|
Metformin
|
DB00331 |
[Metformin is an antihyperglycemic agent of the _biguanide_ class, used for the management of type II diabetes) [FDA label]. Currently, metformin is the first drug of choice for the management of type II diabetes and is prescribed to at least 120 million people worldwide [A176173].
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. Metformin is commonly described as an _insulin sensitizer_ leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels [A176173]. Another well-known benefit of this drug is modest weight loss. Metformin is the drug of choice for obese type II diabetes patients [A36559].
Metformin was first approved in Canada in 1972 [A36552], followed by 1995 in the USA [FDA label]. This drug is available in regular and extended-release forms [FDA label].] |
|
Trans-O-Hydroxy-Alpha-Methyl Cinnamate
|
DB01662 |
|
|
C16-Fatty-Acyl-Substrate-Mimic
|
DB02990 |
|
|
S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea
|
DB02991 |
|
|
1-(5-phospho-D-ribosyl)-ATP
|
DB01661 |
|
|
Ethambutol
|
DB00330 |
[An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863)] |
|
Antroquinonol
|
DB12326 |
[Antroquinonol has been used in trials studying the treatment of Hyperlipidemias, Non-small Cell Lung Cancer, and Non-small Cell Lung Cancer Stage IV.] |
|
Benorilate
|
DB13657 |
|
|
Umbralisib
|
DB14989 |
[Umbralisib is under investigation in clinical trial NCT02535286 (Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation).] |
|
Dalantercept
|
DB14988 |
[Dalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma).] |
|
Salvinorin A
|
DB12327 |
[Salvinorin A has been investigated for the basic science of Pharmaceutical Preparations.] |
|
Hemoglobin raffimer
|
DB13658 |
|
|
Cantharidin
|
DB12328 |
[Cantharidin is a naturally occurring odorless, colorless fatty substance of the terpenoid class that is produced as an oral fluid in the alimentary canal of the male blister beetle [A32891, A32892]. For its natural purpose, the male blister beetle secretes and presents the cantharidin to a female beetle as a copulatory gift during mating. Post-copulation, the female beetle places the cantharidin over her eggs as protection against any potential predators.
Available synthetically since the 1950s, topical applications of cantharidin have been used predominantly as a treatment for cutaneous warts since that time [A32891, A32892]. In 1962 however, marketers of cantharidin failed to produce sufficient efficacy data, resulting in the FDA revision of approval of cantharidin [A32892].
Today, topcial cantharidin products do not necessarily demonstrate any particular better effectiveness at treating topical skin conditions like warts than other commonly available vesicant and/or keratolytics although various studies have also investigated the possibility of using cantharidin as an inflammatory model or in cancer treatment [A32892]. Regardless, the onging lack of FDA approval is likely related to certain toxic effects that were observed following oral ingestion, which includes ulceration of the gastrointestinal and genitourinary tracts, along with electrolyte and renal function disturbance in humans and animals [A32891].] |
|
Tenonitrozole
|
DB13659 |
|
|
Eravacycline
|
DB12329 |
[Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens [A38683]. It was first approved by the FDA on August 27, 2018 [L4540]. Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections [A38727].] |
|
Lorcainide
|
DB13653 |
|
|
GW-870086
|
DB12322 |
[GW870086X has been investigated for the treatment of ASTHMA.] |
|
Enarodustat
|
DB14985 |
[Enarodustat is under investigation in clinical trial NCT02581124 (Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease).] |
|
Casimersen
|
DB14984 |
[Casimersen is under investigation in clinical trial NCT03532542 (An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy).] |
|
Montmorillonite
|
DB13654 |
|
